Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The hypoxia-responsive long non-coding RNAs may impact on the tumor biology and subsequent management of breast cancer

A. Kapinova, P. Kubatka, P. Zubor, O. Golubnitschaja, Z. Dankova, S. Uramova, I. Pilchova, M. Caprnda, R. Opatrilova, J. Richnavsky, P. Kruzliak, J. Danko,

. 2018 ; 99 (-) : 51-58. [pub] 20180108

Jazyk angličtina Země Francie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc18033398

Long non-coding RNAs (lncRNAs) are DNA transcripts longer than 200 nucleotides without protein-coding potential. As they are key regulators of gene expression at chromatic, transcriptional and posttranscriptional level, they play important role in various biological and pathological processes. Dysregulation of lncRNAs has been observed in several diseases including cancer. Breast cancer is heterogeneous disease with many molecular subtypes specific in different prognosis and treatment responses. Hypoxia, a common micro-environmental feature of rapidly growing tumour is associated with metastases, recurrences and resistance to therapy. Aberrant expression of hypoxia related lncRNAs significantly correlates with poor outcomes in cancer patients, as the lncRNAs play an important regulatory role in the breast cancer-cell survival. Thus, a better understanding of lncRNAs role in the hypoxic conditions of breast cancer is crucial for precise understanding of the tumorigenesis, disease features and poor clinical outcome, especially in highly aggressive breast cancer subtypes (HER2-positive and triple-negative types). Moreover, lncRNAs may represent tumour marker predicting prognosis and therapeutic targets improving precise and personalized therapy for better patient´s survival. In this review, we summarize the recent information on lncRNAs in breast cancer with special focus on the hypoxia-responsive lncRNAs and their potential impact on the prognosis, therapy algorithms and individual outcomes. Presented data helps in better understanding of the specific mechanisms predicting new therapeutic agents and strategies for the pharmacological intervention.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033398
003      
CZ-PrNML
005      
20210219152239.0
007      
ta
008      
181008s2018 fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.biopha.2017.12.104 $2 doi
035    __
$a (PubMed)29324312
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Kapinova, Andrea $u Division of Oncology, Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia. Electronic address: kapinova@jfmed.uniba.sk.
245    14
$a The hypoxia-responsive long non-coding RNAs may impact on the tumor biology and subsequent management of breast cancer / $c A. Kapinova, P. Kubatka, P. Zubor, O. Golubnitschaja, Z. Dankova, S. Uramova, I. Pilchova, M. Caprnda, R. Opatrilova, J. Richnavsky, P. Kruzliak, J. Danko,
520    9_
$a Long non-coding RNAs (lncRNAs) are DNA transcripts longer than 200 nucleotides without protein-coding potential. As they are key regulators of gene expression at chromatic, transcriptional and posttranscriptional level, they play important role in various biological and pathological processes. Dysregulation of lncRNAs has been observed in several diseases including cancer. Breast cancer is heterogeneous disease with many molecular subtypes specific in different prognosis and treatment responses. Hypoxia, a common micro-environmental feature of rapidly growing tumour is associated with metastases, recurrences and resistance to therapy. Aberrant expression of hypoxia related lncRNAs significantly correlates with poor outcomes in cancer patients, as the lncRNAs play an important regulatory role in the breast cancer-cell survival. Thus, a better understanding of lncRNAs role in the hypoxic conditions of breast cancer is crucial for precise understanding of the tumorigenesis, disease features and poor clinical outcome, especially in highly aggressive breast cancer subtypes (HER2-positive and triple-negative types). Moreover, lncRNAs may represent tumour marker predicting prognosis and therapeutic targets improving precise and personalized therapy for better patient´s survival. In this review, we summarize the recent information on lncRNAs in breast cancer with special focus on the hypoxia-responsive lncRNAs and their potential impact on the prognosis, therapy algorithms and individual outcomes. Presented data helps in better understanding of the specific mechanisms predicting new therapeutic agents and strategies for the pharmacological intervention.
650    _2
$a nádory prsu $x genetika $x patologie $x terapie $7 D001943
650    _2
$a hypoxie buňky $x genetika $7 D015687
650    _2
$a klinické zkoušky jako téma $7 D002986
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a RNA dlouhá nekódující $x genetika $x metabolismus $7 D062085
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Kubatka, Peter $u Division of Oncology, Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia; Department of Medical Biology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia.
700    1_
$a Žúbor, Pavol, $d 1975- $u Division of Oncology, Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia; Department of Obstetrics and Gynecology, Jessenius Faculty of Medicine in Martin and Martin University Hospital, Comenius University in Bratislava, Martin, Slovakia. $7 xx0117542
700    1_
$a Golubnitschaja, Olga $u Radiological Clinic, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany; Breast Cancer Research Centre, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany; Centre for Integrated Oncology, Cologne-Bonn, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany.
700    1_
$a Danková, Zuzana $7 xx0227948 $u Division of Oncology, Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia.
700    1_
$a Uramova, Sona $u Department of Obstetrics and Gynecology, Jessenius Faculty of Medicine in Martin and Martin University Hospital, Comenius University in Bratislava, Martin, Slovakia.
700    1_
$a Pilchova, Ivana $u Division of Neuroscience, Biomedical Center Martin, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia.
700    1_
$a Caprnda, Martin $u 1st Department of Internal Medicine, Faculty of Medicine, Comenius University in Bratislava and University Hospital, Bratislava, Slovakia.
700    1_
$a Opatrilova, Radka $u Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic.
700    1_
$a Richnavsky, Jan $u Department of Gynecology and Obstetrics, Faculty of Medicine, Pavol Jozef Safarik University and The First Private Hospital Saca, Kosice, Slovakia.
700    1_
$a Kruzliak, Peter $u Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic. Electronic address: kruzliakp@vfu.cz.
700    1_
$a Danko, Jan $u Department of Obstetrics and Gynecology, Jessenius Faculty of Medicine in Martin and Martin University Hospital, Comenius University in Bratislava, Martin, Slovakia.
773    0_
$w MED00005486 $t Biomedicine & pharmacotherapy Biomedecine & pharmacotherapie $x 1950-6007 $g Roč. 99, č. - (2018), s. 51-58
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29324312 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20210219152237 $b ABA008
999    __
$a ok $b bmc $g 1340135 $s 1030392
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 99 $c - $d 51-58 $e 20180108 $i 1950-6007 $m Biomedicine & pharmacotherapy $n Biomed Pharmacother $x MED00005486
LZP    __
$a Pubmed-20181008

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace